Toll Free: 1-888-928-9744
Published: Mar, 2015 | Pages:
32 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2015 Summary Global Markets Direct’s, ‘Organophosphate And Carbamate Poisoning - Pipeline Review, H1 2015’, provides an overview of the Organophosphate And Carbamate Poisoning’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Organophosphate And Carbamate Poisoning, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Organophosphate And Carbamate Poisoning and special features on late-stage and discontinued projects. Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Organophosphate And Carbamate Poisoning - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Organophosphate And Carbamate Poisoning and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Organophosphate And Carbamate Poisoning products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Organophosphate And Carbamate Poisoning pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Organophosphate And Carbamate Poisoning - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Organophosphate And Carbamate Poisoning pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Organophosphate And Carbamate Poisoning Overview 6 Therapeutics Development 7 Pipeline Products for Organophosphate And Carbamate Poisoning - Overview 7 Pipeline Products for Organophosphate And Carbamate Poisoning - Comparative Analysis 8 Organophosphate And Carbamate Poisoning - Therapeutics under Development by Companies 9 Organophosphate And Carbamate Poisoning - Therapeutics under Investigation by Universities/Institutes 10 Organophosphate And Carbamate Poisoning - Pipeline Products Glance 11 Early Stage Products 11 Organophosphate And Carbamate Poisoning - Products under Development by Companies 12 Organophosphate And Carbamate Poisoning - Products under Investigation by Universities/Institutes 13 Organophosphate And Carbamate Poisoning - Companies Involved in Therapeutics Development 14 Countervail Corporation 14 Organophosphate And Carbamate Poisoning - Therapeutics Assessment 15 Assessment by Monotherapy Products 15 Assessment by Target 16 Assessment by Mechanism of Action 18 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Drug Profiles 24 AM-132 - Drug Profile 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 galantamine - Drug Profile 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 Small Molecule for Organophosphate Poisoning - Drug Profile 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 Small Molecule to Inhibit PARP-1 and Activate AChE for Organophosphates Poisoning - Drug Profile 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 Small Molecules to Activate Acetylcholinesterase for Organophosphate Poisoning - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Organophosphate And Carbamate Poisoning - Discontinued Products 30 Appendix 31 Methodology 31 Coverage 31 Secondary Research 31 Primary Research 31 Expert Panel Validation 31 Contact Us 31 Disclaimer 32
List of Tables Number of Products under Development for Organophosphate And Carbamate Poisoning, H1 2015 7 Number of Products under Development for Organophosphate And Carbamate Poisoning - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Early Stage Development, H1 2015 11 Products under Development by Companies, H1 2015 12 Products under Investigation by Universities/Institutes, H1 2015 13 Organophosphate And Carbamate Poisoning - Pipeline by Countervail Corporation, H1 2015 14 Assessment by Monotherapy Products, H1 2015 15 Number of Products by Stage and Target, H1 2015 17 Number of Products by Stage and Mechanism of Action, H1 2015 19 Number of Products by Stage and Route of Administration, H1 2015 21 Number of Products by Stage and Molecule Type, H1 2015 23 Organophosphate And Carbamate Poisoning - Discontinued Products, H1 2015 30
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.